SONA is open for business.... Dear Interested Partners,
Sona Nanotech Inc. is pleased to announce that its rapid detection, COVID-19 antigen test validation studies of performance levels have resulted in a test sensitivity of 96%, test specificity of 96% and a Limit of Detection ("LOD") of 2.1 x 102 TCID50. Validation studies were conducted to assess the test's potential clinical performance using 30 nasopharyngeal samples from healthy individuals who were presumed negative for COVID-19.
For additional details, please read July 2nd Press Release:
https://sonanano.com/sona-nanotech-announces-validation-results-for-its-covid-19-antigen-test/ As the pandemic continues and the understanding of COVID-19 improves, regulators have placed greater emphasis on clinical, 'in-field' evaluations of rapid tests at the point of care to ensure they can be deployed with confidence. Following consultation with MRIGlobal and the FDA, Sona will enter into independent clinical, in-field evaluation studies to generate the data to support its analytical and clinical data as part of the submission it will make to Health Canada and the FDA for emergency use authorization ("EUA") approval.
The Company is inviting interested partners, the opportunity to begin partnership agreement discussions. Please advise on your interest in proceeding, and we would look forward to speaking with you at your earliest convenience.
Many Thanks,
Dianna
Dianna Lesperance | Business Development Analyst